BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2251521)

  • 1. Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease.
    Henry-Amar M; Somers R
    Semin Oncol; 1990 Dec; 17(6):758-68. PubMed ID: 2251521
    [No Abstract]   [Full Text] [Related]  

  • 2. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
    Hasenclever D; Diehl V
    N Engl J Med; 1998 Nov; 339(21):1506-14. PubMed ID: 9819449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease.
    Mauch PM; Kalish LA; Marcus KC; Shulman LN; Krill E; Tarbell NJ; Silver B; Weinstein H; Come S; Canellos GP; Coleman CN
    Cancer J Sci Am; 1995; 1(1):33-42. PubMed ID: 9166452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long survival in Hodgkin's disease.
    Henry L
    Clin Radiol; 1970 Apr; 21(2):203-10. PubMed ID: 5420269
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence of secondary malignancies in patients with Hodgkin's disease: preliminary results.
    Slanina J; Henne K; Schäffer G; Hodapp N; Moog G; Frommhold H
    Recent Results Cancer Res; 1993; 130():269-77. PubMed ID: 8362096
    [No Abstract]   [Full Text] [Related]  

  • 6. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD).
    Gobbi PG; Comelli M; Grignani GE; Pieresca C; Bertoloni D; Ascari E
    Haematologica; 1994; 79(3):241-55. PubMed ID: 7926973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hodgkin's disease--a curable disease].
    Kotlarek-Haus S; Gabryś K; Sciborski R; Gałazka Z; Jeleń M; Fischer W
    Pol Tyg Lek; 1988 Aug; 43(33):1047-52. PubMed ID: 3244571
    [No Abstract]   [Full Text] [Related]  

  • 8. International Database on Hodgkin's Disease: a cooperative effort to determine treatment outcome.
    Mauch P; Henry-Amar M
    Ann Oncol; 1992 Sep; 3 Suppl 4():59-61. PubMed ID: 1450081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival after recurrence: prognostic factors and spread patterns in clinical stages I and II of Hodgkin's disease.
    Tubiana M; van der Werf-Messing B; Laugier A; Hayat M; Henry-Amar M; Attie E; Leroy T
    Natl Cancer Inst Monogr; 1973 May; 36():513-30. PubMed ID: 4744607
    [No Abstract]   [Full Text] [Related]  

  • 10. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hodgkin's disease survival by stage and age.
    Kennedy BJ; Fremgen AM; Menck HR
    J Am Geriatr Soc; 2000 Mar; 48(3):315-7. PubMed ID: 10733060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group.
    Kreissl S; Mueller H; Goergen H; Mayer A; Brillant C; Behringer K; Halbsguth TV; Hitz F; Soekler M; Shonukan O; Rueffer JU; Flechtner HH; Fuchs M; Diehl V; Engert A; Borchmann P;
    Lancet Oncol; 2016 Oct; 17(10):1453-1462. PubMed ID: 27612583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of various factors on the survival period in Hodgkin's disease].
    Gabryś K; Sciborski R; Gałazka Z; Smakowska E; Kotlarek-Haus S
    Pol Tyg Lek; 1982 Jul; 37(24-25):713-5. PubMed ID: 7177968
    [No Abstract]   [Full Text] [Related]  

  • 14. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group.
    Josting A; Franklin J; May M; Koch P; Beykirch MK; Heinz J; Rudolph C; Diehl V; Engert A
    J Clin Oncol; 2002 Jan; 20(1):221-30. PubMed ID: 11773173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
    J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
    Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
    Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.
    Ng AK; Bernardo MP; Weller E; Backstrand KH; Silver B; Marcus KC; Tarbell NJ; Friedberg J; Canellos GP; Mauch PM
    J Clin Oncol; 2002 Apr; 20(8):2101-8. PubMed ID: 11956271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.
    André M; Henry-Amar M; Pico JL; Brice P; Blaise D; Kuentz M; Coiffier B; Colombat P; Cahn JY; Attal M; Fleury J; Milpied N; Nedellec G; Biron P; Tilly H; Jouet JP; Gisselbrecht C
    J Clin Oncol; 1999 Jan; 17(1):222-9. PubMed ID: 10458237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.